VIENNA, Va., September 16, 2024--CEL-SCI’s Multikine Increased 5-Year Survival Rate in Locally Advanced Resectable Head & Neck Cancer Patients Deemed to be in the Treatment Group. VIENNA, Va., ...
Some results have been hidden because they may be inaccessible to you